BMS-986463
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High-grade Serous Ovarian Carcinoma (HGSOC)
Conditions
High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)
Trial Timeline
Sep 6, 2024 → Dec 19, 2028
NCT ID
NCT06476808About BMS-986463
BMS-986463 is a phase 1 stage product being developed by Bristol Myers Squibb for High-grade Serous Ovarian Carcinoma (HGSOC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06476808. Target conditions include High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06476808 | Phase 1 | Recruiting |
Competing Products
8 competing products in High-grade Serous Ovarian Carcinoma (HGSOC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 52 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 52 |
| Mebendazole | Brain Biotech | Phase 1 | 25 |
| Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells | Brain Biotech | Phase 1 | 25 |
| APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Aprea Therapeutics | Phase 1/2 | 33 |
| APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Aprea Therapeutics | Phase 2 | 44 |